A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Etoposide; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 27 May 2013 Biomarkers information updated
- 05 Mar 2008 Status changed from in progress to completed, according to ClinicalTrials.gov
- 14 Sep 2005 New trial record.